Open AccessRecommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation
Author(s) -
Mesut Akarsu,
Soner Önem,
İlker Turan,
Gupse Adalı,
Meral Akdoğan,
Murat Akyıldız,
Murat Aladağ,
Yasemin Balaban,
Nilay Danış,
Murat Dayangaç,
Genco Gençdal,
Hale Gökcan,
Elif Sertesen,
Merve Gürakar,
Murat Harputluoğlu,
Gökhan Kabaçam,
Sedat Karademir,
Murat Kıyıcı,
Ramazan İdilman,
Zeki Karasu
Publication year - 2021
Publication title -
digital collections portal (koç university)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.404
H-Index - 28
eISSN - 2148-5607
DOI - 10.5152/tjg.2021.21608
Subject(s) - medicine , liver transplantation , hepatitis b virus , hepatitis b , antibody , liver disease , immunology , transplantation , virology , virus , gastroenterology
The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t) ide analogs after liver transplantation.